Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH1 R132X |
| Therapy | Olaparib |
| Indication/Tumor Type | chondrosarcoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132X | chondrosarcoma | no benefit | Olaparib | Phase II | Actionable | In a Phase II trial, Lynparza (Olaparib) treatment did not demonstrate activity in patients with advanced solid tumors (n=26), including chondrosarcoma (n=14), harboring IDH1 mutations (R132C, n=12) with no objective responses, a median progression-free survival of 2 months, and a median overall survival of 7.5 months (J Clin Oncol 2025 43: 16_suppl, 3087; NCT03212274). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors. | Full reference... |